Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study)

This study attempted to identify factors associated with mortality among human immunodeficiency virus (HIV)–infected adults starting a protease inhibitor (PI)–containing therapy. Among 1155 patients consecutively enrolled in the APROCO study between May 1997 and June 1998, clinical characteristics w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 2002-09, Vol.186 (5), p.710-714
Hauptverfasser: Lewden, Charlotte, Raffi, François, Cuzin, Lise, Cailleton, Valérie, Vildé, Jean-Louis, Chêne, Geneviève, Allavena, Clotilde, Salamon, Roger
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study attempted to identify factors associated with mortality among human immunodeficiency virus (HIV)–infected adults starting a protease inhibitor (PI)–containing therapy. Among 1155 patients consecutively enrolled in the APROCO study between May 1997 and June 1998, clinical characteristics were as follows: median age, 36 years; median baseline CD4 cell count, 288 cells/mm3; and median baseline plasma HIV RNA load, 4.4 log10 copies/mL. After a median follow-up of 27 months, 48 deaths had occurred, of which 44% were related to acquired immune deficiency syndrome. The mortality rate was 2.9% at 12 months. When both data at baseline and data at 4 months after the start of PI therapy were considered, factors independently associated with mortality were (Cox model) low baseline plasma creatinine level, low school education level, low CD4 cell count at 4 months, low hemoglobin level, and elevated hepatic transaminase levels. Thus, social context plus clinical and biologic data, including the 4-month response to treatment, must be considered in treatment of HIV-infected patients
ISSN:0022-1899
1537-6613
DOI:10.1086/342047